Login to Your Account

Molecular Insight Prices $70M IPO For Radiotherapeutics

By Jennifer Boggs

Monday, February 5, 2007
As the first biotech firm to hit the public market via an initial public offering in 2007, Molecular Insight Pharmaceuticals Inc. is bringing in about $70 million to fund ongoing development work on its radiotherapeutics in cancer and its upcoming pivotal study of a molecular imaging agent in heart disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription